Endothelin-1 (ET-1), a circulating vasoactive peptide with potent vasoconstricting and mitogenic properties, may contribute to target-organ damage in hypertension. We investigated whether plasma levels of C-terminal pro-endothelin-1 (CT-pro-ET-1) are associated with left ventricular (LV) mass and aortic root diameter in African-American adults with hypertension. Plasma CTpro-ET-1 was measured by an immunoluminometric assay in 1041 African Americans (65 ± 9 years, 72% women) with hypertension. LV mass and aortic root diameter were measured according to the American Society of Echocardiography guidelines, and LV mass was indexed by height to the power 2.7 (LVMi). Multivariable regression analyses were used to assess whether plasma CT-pro-ET-1 was associated with LVMi and aortic root diameter, independent of potential confounding variables. Plasma CT-pro-ET-1 was modestly correlated with LVMi (r ¼ 0.21, Po0.0001) and aortic root diameter (r ¼ 0.09, P ¼ 0.004). In separate multivariable regression models that adjusted for age, sex, body mass index, total and high-density lipoprotein cholesterol, smoking history, diabetes, history of myocardial infarction or stroke, and blood pressure-lowering medication and statin use, log CT-pro-ET-1 was significantly associated with greater LVMi (P ¼ 0.001) and larger aortic root diameter (P ¼ 0.006). CT-pro-ET-1 is independently associated with LVMi and aortic root diameter and may be a marker of target-organ damage in African-Americans adults with hypertension.
Introduction
Endothelin (ET)-1 is a 21-amino-acid vasoactive peptide, derived mainly from vascular endothelial cells 1 but also produced by vascular smooth muscle cells, 1 cardiac myocytes, 2 and fibroblasts. 3 The initial product of human ET-1 gene is a 212 aminoacid peptide, pre-pro-ET-1, which is converted to pro-ET-1 after removal of a short amino-acid sequence. 2 Pro-ET-1 is cleaved to a 38-amino-acid precursor, big ET-1, which is finally modified by the ET-1-converting enzyme to produce ET-1.
2 ET-1 acts by binding to two distinct receptors (ET A and ET B ), found on vascular smooth muscle cells and the myocardium. 2 ET-1 mediates vasoconstriction by binding to ET A receptors on the underlying smooth muscle cells, augments sympathetic activity, increases sodium retention, activates the renin-angiotensin-aldosterone system, and induces myocardial hypertrophy and hypertrophic remodelling of small arteries in hypertension. 2 ET-1 acts in an autocrine and/or paracrine manner and most of the ET-1 produced by the endothelium is secreted towards the adjacent vascular smooth muscle cells. 4 Thus, plasma ET-1 levels reflect spillover in to the circulation rather than actual ET-1 production. Reliable quantification of plasma ET-1 has been impeded by its short plasma half-life (1-2 min), 5 its nonspecific binding to plasma proteins, 6 and its immediate clearance by binding to receptors during pulmonary passage. 7 Recently, an immunoluminometric assay for the measurement of C-terminal fragment of pre-pro-ET-1 (CT-pro-ET-1), a stable nonfunctional peptide that is produced in equimolar amount to ET-1, has been validated for measuring ET-1 activity in the plasma and may provide a better assessment of the actual release of ET-1 gene products. 8 Left ventricular (LV) hypertrophy and aortic root dilation are well-recognized manifestations of target-organ damage in patients with hypertension and are associated with increased cardiovascular morbidity and mortality. [9] [10] [11] Early detection of target-organ damage in patients with hypertension is of utmost interest in clinical practice. Although clinical variables such as age, diabetes and hyperlipidemia are established risk factors for acceleration of arteriosclerosis and consequent target-organ damage in patients with hypertension, much of the interindividual variation in measures of target-organ damage cannot be accounted for solely by known clinical risk factors. New biomarkers in etiologic pathways of target-organ damage may explain some of the remaining interindividual variability and may facilitate early detection of target-organ damage in hypertension. African Americans have a disproportionate burden of hypertension, and AfricanAmerican hypertensives are more prone to adverse cardiovascular events and hypertension-related target-organ damage compared with hypertensives from other ethnic groups. 12 Although ET-1 has been implicated in the development and maintenance of hypertension, particularly in African Americans little is known about its role in mediating targetorgan damage. We hypothesized that plasma levels of CT-pro-ET-1 may be associated with echocardiographic measures of target-organ damage-LV mass and aortic root diameter-in African Americans with hypertension.
Patients and methods
This study was part of the Proteomic Markers of Arteriosclerosis Study, which is investigating the association of multiple markers in various etiologic pathways of vascular diseases with several phenotypes of arteriosclerosis. 13 Participants were members of sibships that were initially enrolled in Jackson MS between June 1996 and August 2000 in the Genetic Epidemiology Network of Arteriopathy study, a multicenter, community-based study that aims to identify genetic variants influencing blood pressure (BP) levels and the development of target-organ damage due to hypertension.
14 The Jackson MS cohort of Atherosclerosis Risk in Communities study that had originally been a probability sample of persons with driver's licenses was used to ascertain African-American sibships. Participants were enrolled if two or more members of a sibship had hypertension. The only exclusionary criterion at enrollment was the presence of a secondary cause of hypertension (such as documented renal artery stenosis or advanced renal insufficiency) in the index sibs. Study protocols were approved by the human studies review board at the University of Mississippi Medical Center. Written informed consent was obtained from each participant. This study included 1041 African Americans who had hypertension. Normotensive subjects were excluded.
Methods used to measure height, weight, resting systolic BP and diastolic BP and the definitions of clinical conditions have been described earlier. 15 Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters. Blood was drawn after an overnight fast. Serum creatinine, glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol and triglyceride concentrations were measured by standard methods on a Hitachi 911 Chemistry analyzer (Roche Diagnostics, Indianapolis, IN, USA). Estimated glomerular filtration rate (eGFR) was calculated using the abbreviated equation from the Modification of Diet in Renal Disease Study using standardized serum creatinine value. 16 Plasma levels of CT-pro-ET-1 Plasma was collected at the time of blood sampling in plastic vials containing ethylenediaminetetraacetic acid. Samples were placed on ice and then centrifuged at 3000 g and frozen at À80 1C until assayed. Plasma CT-pro-ET-1 was measured by a commercial assay in the chemiluminescence/coated tube-format (BRAHMS AG, Hennigsdorf/Berlin, Germany) as described earlier. 8 Briefly, tubes were coated with a purified sheep polyclonal antibody raised against a peptide representing amino acids 168-181 of pre-pro-ET-1. A purified sheep polyclonal antibody raised against a peptide representing amino acids 200-212 of pre-pro-ET-1 was labelled with MACN acridinium-NHS ester (InVent GmbH, Braunschweig, Germany) and used as tracer. Dilutions of a peptide representing amino acids 169-212 of pre-pro-ET-1 in normal horse serum served as standards. The immunoassay was performed by incubating 50 ml of samples/standards and 200 ml of tracer in coated tubes for 2 h at room temperature. Tubes were washed four times with 1 ml of LIA wash solution (BRAHMS AG), and bound chemiluminescence was measured using a LB952T luminometer (Berthold, Bad Wildbad, Germany). The assay (mean reference range, 44.3± 10.6 pmol l À1 ) has an analytical detection limit of 0.4 pmol l À1 . As plasma CT-pro-ET-1 values o10 pmol l À1 are likely to reflect degradation, 59 participants with levels o10 pmol l À1 were excluded from our analyses.
Echocardiographic measures
Participants were examined with two-dimensional and Doppler echocardiography on an Acuson 128XP/10c (Acuson, Malvern, PA, USA) using 2.5-, 3.5-and 5.0-MHz transducers while in the lateral decubitus position. A standardized protocol was followed under which the parasternal long-and short-axis views were used to record on videotape 10 or more consecutive beats of two-dimensional and M-mode recordings. LV internal dimension, LV septal wall thickness and LV posterior wall thickness were measured at end-diastole and endsystole according to American Society of Echocardiography recommendations, averaging three or more cardiac cycles. Correct orientations of planes for imaging and Doppler recordings were verified using standardized protocols. LV mass was derived from the simplified cubed equation formula 17 and indexed by height to the power 2.7 (LVMi) to normalize heart size to body size. LV hypertrophy was defined as an LVMi of X51 g m À2.7 in men and women. Relative wall thickness was calculated as the sum of LV septal and posterior wall thickness at end-diastole divided by LV internal dimension at end-diastole. The LV ejection fraction was calculated using the modified Quinones method. 18 Aortic root diameter was measure in the parasternal long-axis view, using colour flow mapping to help delineate tissue-blood interfaces when necessary, at sinuses of Valsalva level by M-mode tracings. The maximal distance between the two leading edges of the anterior and posterior aortic root walls at the end-diastole was taken as the aortic root diameter. 19 
Statistical methods
Statistical analyses were performed using SAS v 9.1 (SAS Institute, Cary, NC, USA). Because of sibships in the sample, we used generalized estimating equations to account for intrafamilial correlations. Continuous variables were expressed as mean ± s.d. Categorical variables were expressed as number (percentage). Values for plasma CT-pro-ET-1, LVMi and eGFR were log transformed to minimize skewness. Spearman correlation coefficients were used to assess the correlation between CT-pro-ET-1 levels with LVMi and aortic root diameter. We used multivariable regression analyses to identify variables independently associated with plasma CT-pro-ET-1 from among age, sex, BMI, systolic BP, diastolic BP, total and HDL cholesterol, smoking history, diabetes, history of myocardial infarction or stroke, and the use of BP-lowering medications (diuretics, b-blockers, calcium-channel blockers or reninangiotensin-aldosterone system inhibitors) and statins. Initially, we constructed separate univariable linear regression models to assess whether plasma CT-pro-ET-1 was associated with LVMi, LV posterior wall thickness, LV septal wall thickness, LV relative wall thickness and aortic root diameter. Next, we constructed separate multivariable linear regression models that adjusted for age and sex, and additionally for conventional cardiovascular risk factors (BMI, systolic BP, diastolic BP, total and HDL cholesterol, smoking history and diabetes), history of myocardial infarction or stroke, and the use of BP-lowering medications and statins. Statistical significance was determined at two-sided P-value of o0.05.
Results
The characteristics of the study participants are shown in Tables 1 and 2 . Of the 1041 participants, 754 (72.4%) were women and 346 (33.2%) had diabetes. The mean plasma CT-pro-ET-1 level was 50.68 pmol l À1 and the median level was 49.05 pmol l À1 . Plasma levels of CT-pro-ET-1 increased with greater age, higher systolic BP, lower eGFR, lower HDL-cholesterol, and were higher in Endothelin-1 and left ventricular mass in hypertension MA Al-Omari et al subjects with history of myocardial infarction and/ or stroke (Table 3) . A significant proportion (19%) of the interindividual variation in plasma levels of CTpro-ET-1 could be explained by these clinical variables. Plasma CT-pro-ET-1 was significantly correlated with LVMi (r ¼ 0.21, Po0.0001) (Figure 1 ). After adjustment for age and sex, log CT-pro-ET-1 was significantly associated with log LVMi (Po0.001), LV posterior wall thickness (P ¼ 0.002), LV septal wall thickness (P ¼ 0.003) and the presence of LV hypertrophy (P ¼ 0.002) but not LV relative wall thickness, left atrial diameter or LV ejection fraction (analyses not shown). After additional adjustment for cardiovascular risk factors and medication use, log CT-pro-ET-1 remained significantly associated with greater log LVMi (P ¼ 0.002) ( Table 4) . Other variables associated with greater log LVMi included age, higher BMI, higher systolic BP, history of MI and/or stroke, diabetes, use of b-blockers and/or calcium channel blockers (Table 4) . These variables and log CT-pro-ET-1 explained 24% of the interindividual variation of LVMi.
Plasma CT-pro-ET-1 was modestly correlated with aortic root diameter (r ¼ 0.09, P ¼ 0.004) (Figure 1) . After adjustment for age and sex, log CT-pro-ET-1 was significantly associated with aortic root diameter (P ¼ 0.005). After additional adjustment for cardiovascular risk factors and medication use, log CT-pro-ET-1 remained significantly associated with aortic root diameter (P ¼ 0.008). Variables independently associated with larger aortic root diameter were age, male sex, higher BMI, lower systolic BP, higher diastolic BP and log CT-pro-ET-1 (Table 3) . These variables and log CT-pro-ET-1 explained 29% of interindividual variation of aortic root diameter.
Discussion
The concept of measuring a nonfunctional, stable peptide derived from a common precursor peptide instead of the bioactive, rapidly cleared peptide has been applied with success in the case of natriuretic peptides. 20, 21 In this study, we measured plasma levels of CT-pro-ET-1, a nonfunctional, stable fragment of an ET-1 precursor, in a community-based sample of African Americans with hypertension, and observed that higher plasma CT-pro-ET-1 levels were associated with greater LVMi and greater The mean/median levels of plasma CT-pro-ET-1 in our study were higher than the previously reported mean/median levels in apparently healthy individuals (44.3 pmol l À1 /B45 pmol l À1 ), likely due to the fact that all participants in our study had hypertension. Consistent with earlier reports, 8, 22 we found plasma levels of CT-pro-ET-1 to be higher in older subjects and to be similar in men and women. In addition, we found that higher systolic BP, higher heart rate, lower eGFR, lower HDL cholesterol and history of MI and stroke were additional independent predictors of higher plasma CT-pro-ET-1 levels in African-American adults with hypertension (Table 3) . Renal filtration is an important determinant of plasma CT-pro-ET-1 levels; consideration of a confounding effect of decreased renal function on any observed association between plasma CT-pro-ET-1 levels and target-organ damage manifestations in hypertensives is pertinent. In our study, however, the observed association between plasma CT-pro-ET-1 and LVMi and aortic root diameter were independent of eGFR.
Plasma ET-1 levels were reported to be higher in hypertensives with LV hypertrophy than in hypertensives without LV hypertrophy. [23] [24] [25] Earlier studies that evaluated the associations of ET-1 with LVMi were relatively small (np120) and the results were not consistent. Three of them reported a significant association of plasma CT-pro-ET-1 with LVMi, 23, 24, 26 whereas two studies found no significant association. [27] [28] [29] In our study, plasma CT-pro-ET-1 was associated with LVMi after adjustment for conventional cardiovascular risk factors and medication use (P ¼ 0.002). In addition, after further adjustment for aortic root diameter and LV ejection fraction, plasma CT-pro-ET-1 remained significantly associated with LVMi (P ¼ 0.008). Moreover, using LVMi X51 g m À2.7 to define LV hypertrophy in both sexes, higher plasma CT-pro-ET-1 was associated with LV hypertrophy after multivariable adjustment (P ¼ 0.025) (analyses not shown). Consistent with an earlier report, 26 we found plasma CT-pro-ET-1 to be associated with LV relative wall thickness in univariate analyses only. We did not find a significant association with left atrial diameter and LV ejection fraction. Left atrial volume is a more accurate measurement of left atrial size than left atrial diameter but the required images to calculate left atrial volume were not available for this study.
LV hypertrophy is more prevalent in African Americans 12 and is associated with increased cardiovascular morbidity and mortality. 9, 10 Earlier studies suggest that the sympathetic nervous system activity and the renin-angiotensin-aldosterone system contribute to the development and maintenance of LV hypertrophy by inducing myocardial hypertrophy and fibrosis. Multiple animal studies suggest a role of ET-1 in the development of myocardial hypertrophy. [30] [31] [32] ET-1 is secreted by cardiac myocytes and fibroblasts in response to mechanical stretching and pressure overload, 32 in turn promoting cardiac 33 and enhancing norepinephrine 34 and angiotensin II-induced cardiac hypertrophy. 2 Earlier cross-sectional studies showed that aortic root dilation (defined as aortic root diameter 497.5th percentile predicted by subject's body surface area) is more prevalent in patients with hypertension, 35 associated with LV hypertrophy, 36 other target-organ damage, 36 and adverse cardiovascular events. 11 Aortic root diameter is mainly determined by age and body size, and the impact of BP on aortic root diameter, independent of age and body size, remains controversial. 37 We report for the first time a modest but statistically significant association between plasma CT-pro-ET-1 and aortic root diameter. Other variables that were independently associated with larger aortic root diameter were age, male sex, higher BMI, lower systolic BP, higher diastolic BP (Table 4) . ET-1 may contribute to aortic root dilation by increasing the expression of matrix metalloproteinase. 38, 39 Our findings suggest that plasma level of CT-pro-ET-1 may be a marker of hypertension-related changes in LV mass and aortic root diameter in African-American adults with essential hypertension. Although plasma levels of CT-pro-ET-1 were significantly associated with LVMi, its ability to discriminate between the presence and absence of LV hypertrophy was modest. Using only plasma levels of CT-pro-ET-1 to predict the presence of LV hypertrophy, the area under the receiver operating characteristics curve to predict LV hypertrophy was 0.62 (analysis not shown). Plasma CT-pro-ET-1 may have a clinical utility in the early detection and monitoring the progression of target-organ damage in adults with hypertension, once an individual, steady state of plasma CT-pro-ET-1 level is established.
Several limitations of our study need to be recognized. The generalizability of our findings to other racial/ethnic groups is not established and the cross-sectional design of our study precludes interpretations about causality. In addition, plasma CTpro-ET-1 and echocardiographic measures were measured only once, and variation with time could not be taken into account. However, this would bias the results towards the null and underestimate the true associations. The associations although statistically significant were modest. Most participants (85%) were on BP-lowering medications and although we adjusted for medication use in our analyses, an effect of BP-lowering medications on the observed associations cannot be completely ruled out. However, we did not find a particular class of antihypertensive medications to be associated with plasma CT-pro-ET-1 levels. We adjusted for multiple covariates that may be associated with plasma CT-pro-ET-1 levels or target-organ damage in hypertension. However, the possibility of residual confounding remains.
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